Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164967213> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W3164967213 endingPage "603" @default.
- W3164967213 startingPage "598" @default.
- W3164967213 abstract "Objective: To investigate the genetic abnormality and protein expression of C-MYC and PD-L1 in the patients with ALK-negative anaplastic large cell lymphoma (ALK－ALCL), and to explore their roles in the pathogenesis of ALK－ALCL and their relationship with clinicopathological characteristics. Methods: Thirty-seven cases of ALK－ALCL diagnosed at Fujian Provincial Hospital from January 2003 to January 2017 were selected. Fluorescence in situ hybridization (FISH) was used to detect the genetic abnormality of C-MYC and PD-L1. The expression of C-MYC and PD-L1 proteins was detected by immunohistochemistry. The relationship between C-MYC and PD-L1 genes' abnormalities and protein expression was analyzed, as well as their associations with various clinicopathological parameters. Results: Among the 37 ALK－ALCL patients, 17 (45.9%) were positive for C-MYC protein, and 14 (37.8%) were positive for PD-L1 protein. There was a significant correlation between C-MYC protein and PD-L1 protein (r=0.990,P=0.014). The protein expression of C-MYC and PD-L1 (versus negative) was associated with the clinical stage of ALK－ALCL, respectively. The international prognosis index (IPI) in high-risk group was higher than that in the low-risk group (P<0.05). FISH test showed that 9 (24.3%) of the 37 cases had amplification of C-MYC gene, and no translocation of C-MYC gene was found in any of the cases. Amplification of PD-L1 gene was found in only 2 cases (5.4%). The 3-year overall survival rate of the C-MYC or PD-L1 immunohistochemistry-positive cases was significantly lower than those of the C-MYC or PD-L1 negative cases (P<0.01 and P<0.05), respectively. Conclusion: The expression of C-MYC and PD-L1 proteins are related to the clinical stage, IPI and overall survival rate of ALK－ALCL. Thus, it can be used to assess the disease's aggressiveness and to predict the prognosis of ALK－ALCL. The expression of PD-L1 in ALK－ALCL may be regulated by C-MYC, thus suggesting a possible design of combined C-MYC targeted therapy and immune checkpoint blocking for some ALK－ALCL patients.目的： 探讨C-MYC和PD-L1基因和蛋白在间变性淋巴瘤激酶阴性的间变性大细胞淋巴瘤（ALK－ALCL）患者中的表达，探讨两者在ALK－ALCL发病机制中的作用以及与临床病理特征的关系。 方法： 收集福建省立医院病理科2003年1月至2017年1月ALK－ALCL患者37例，应用荧光原位杂交（FISH）技术检测C-MYC和PD-L1基因异常情况；应用免疫组织化学方法检测C-MYC和PD-L1蛋白表达情况。统计分析C-MYC和PD-L1基因及蛋白异常的关系以及与各临床病理参数间的关系。 结果： 37例ALK－ALCL肿瘤组织中，C-MYC蛋白阳性率为45.9%（17/37），PD-L1蛋白表达阳性率是37.8%（14/37），C-MYC和PD-L1蛋白表达之间存在显著相关性（r=0.990，P=0.014）。C-MYC和PD-L1蛋白表达率均随ALK－ALCL临床分期的增加而升高，且在国际预后指数（IPI）高危组中表达率高于低危组（P<0.05）。FISH检测结果：37例ALK－ALC肿瘤组织中，检测到C-MYC基因多拷贝9例（24.3%），所有病例均未检测到C-MYC基因断裂；检测到PD-L1基因扩增2例（5.4%）。37例ALK－ALCL患者中，C-MYC蛋白阳性表达组3年总生存率明显低于阴性表达组，差异具有统计学意义（P<0.01）；PD-L1蛋白阳性表达组3年总生存率明显低于阴性表达组，差异具有统计学意义（P<0.05）。 结论： C-MYC蛋白和PD-L1蛋白表达与ALK－ALCL临床分期、国际预后指数以及总生存率相关，可作为判断ALK－ALCL恶性程度和预测预后的指标；ALK－ALCL中PD-L1的表达可能受C-MYC基因的调控，可能为设计针对部分ALK－ALCL患者的靶向治疗和免疫检查点阻断的组合治疗提供了生物学基础。." @default.
- W3164967213 created "2021-06-07" @default.
- W3164967213 creator A5015490099 @default.
- W3164967213 creator A5028387628 @default.
- W3164967213 creator A5035787485 @default.
- W3164967213 creator A5077950230 @default.
- W3164967213 date "2021-06-08" @default.
- W3164967213 modified "2023-09-23" @default.
- W3164967213 title "[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma]." @default.
- W3164967213 doi "https://doi.org/10.3760/cma.j.cn112151-20201223-00953" @default.
- W3164967213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34078046" @default.
- W3164967213 hasPublicationYear "2021" @default.
- W3164967213 type Work @default.
- W3164967213 sameAs 3164967213 @default.
- W3164967213 citedByCount "0" @default.
- W3164967213 crossrefType "journal-article" @default.
- W3164967213 hasAuthorship W3164967213A5015490099 @default.
- W3164967213 hasAuthorship W3164967213A5028387628 @default.
- W3164967213 hasAuthorship W3164967213A5035787485 @default.
- W3164967213 hasAuthorship W3164967213A5077950230 @default.
- W3164967213 hasConcept C104317684 @default.
- W3164967213 hasConcept C111829193 @default.
- W3164967213 hasConcept C117643217 @default.
- W3164967213 hasConcept C138626823 @default.
- W3164967213 hasConcept C142724271 @default.
- W3164967213 hasConcept C150194340 @default.
- W3164967213 hasConcept C204232928 @default.
- W3164967213 hasConcept C2776232967 @default.
- W3164967213 hasConcept C2776256026 @default.
- W3164967213 hasConcept C2777542201 @default.
- W3164967213 hasConcept C2777872185 @default.
- W3164967213 hasConcept C2779338263 @default.
- W3164967213 hasConcept C2780942790 @default.
- W3164967213 hasConcept C30481170 @default.
- W3164967213 hasConcept C502942594 @default.
- W3164967213 hasConcept C54355233 @default.
- W3164967213 hasConcept C71924100 @default.
- W3164967213 hasConcept C7602840 @default.
- W3164967213 hasConcept C86803240 @default.
- W3164967213 hasConceptScore W3164967213C104317684 @default.
- W3164967213 hasConceptScore W3164967213C111829193 @default.
- W3164967213 hasConceptScore W3164967213C117643217 @default.
- W3164967213 hasConceptScore W3164967213C138626823 @default.
- W3164967213 hasConceptScore W3164967213C142724271 @default.
- W3164967213 hasConceptScore W3164967213C150194340 @default.
- W3164967213 hasConceptScore W3164967213C204232928 @default.
- W3164967213 hasConceptScore W3164967213C2776232967 @default.
- W3164967213 hasConceptScore W3164967213C2776256026 @default.
- W3164967213 hasConceptScore W3164967213C2777542201 @default.
- W3164967213 hasConceptScore W3164967213C2777872185 @default.
- W3164967213 hasConceptScore W3164967213C2779338263 @default.
- W3164967213 hasConceptScore W3164967213C2780942790 @default.
- W3164967213 hasConceptScore W3164967213C30481170 @default.
- W3164967213 hasConceptScore W3164967213C502942594 @default.
- W3164967213 hasConceptScore W3164967213C54355233 @default.
- W3164967213 hasConceptScore W3164967213C71924100 @default.
- W3164967213 hasConceptScore W3164967213C7602840 @default.
- W3164967213 hasConceptScore W3164967213C86803240 @default.
- W3164967213 hasIssue "6" @default.
- W3164967213 hasLocation W31649672131 @default.
- W3164967213 hasOpenAccess W3164967213 @default.
- W3164967213 hasPrimaryLocation W31649672131 @default.
- W3164967213 hasRelatedWork W10235117 @default.
- W3164967213 hasRelatedWork W11761536 @default.
- W3164967213 hasRelatedWork W12155404 @default.
- W3164967213 hasRelatedWork W3399256 @default.
- W3164967213 hasRelatedWork W460103 @default.
- W3164967213 hasRelatedWork W474796 @default.
- W3164967213 hasRelatedWork W5073757 @default.
- W3164967213 hasRelatedWork W7389565 @default.
- W3164967213 hasRelatedWork W7883632 @default.
- W3164967213 hasRelatedWork W8018899 @default.
- W3164967213 hasVolume "50" @default.
- W3164967213 isParatext "false" @default.
- W3164967213 isRetracted "false" @default.
- W3164967213 magId "3164967213" @default.
- W3164967213 workType "article" @default.